Research on Nutrient Deprivation in Triple-Negative Breast Cancer

The Importance of Nutrition in Cancer Growth

A balanced diet is essential for our growth and development, especially during youth. Interestingly, cancer cells also require specific nutrients to proliferate. Researchers are exploring ways to deprive cancer cells of these nutrients as a treatment strategy, particularly for aggressive cancers like triple-negative breast cancer, which has limited therapeutic options.

Understanding Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is known for its aggressive nature and challenges in diagnosis and treatment. This type of cancer lacks certain cell surface proteins known as receptors, including estrogen, progesterone, and HER2. Consequently, hormonal therapies and Herceptin are ineffective, leaving chemotherapy as the primary treatment option. Ongoing research focuses on the metabolism of cancer cells to discover innovative treatment methods.

Cancer Cell Metabolism

Cancer cells are characterized by rapid growth and division, leading to a high demand for nutrients. Unlike healthy cells, which metabolize glucose via mitochondrial oxidative phosphorylation, cancer cells rely on glycolysis. This metabolic shift, known as the Warburg effect, results in glucose being converted into lactic acid rather than being used to produce citrate, a crucial component in energy production and cellular structure synthesis.

Essential Nutrients for Cancer Cells

Glutamine, an abundant amino acid in plasma, plays a significant role in cancer cell metabolism, converting into citrate through processes involving enzymes like glutaminase. Additionally, some cancer cells can metabolize fatty acids to produce Acetyl-CoA, which also contributes to citrate formation through beta-oxidation. Understanding the nutrient requirements of cancer cells is vital for developing effective treatment strategies.

Strategies to Starve Cancer Cells

Limiting nutrient intake can hinder the growth of cancer cells, similar to how dieting restricts weight gain in humans. The challenge lies in identifying which nutrients are essential for specific cancer types. Small molecule inhibitors, such as CB-839, can block enzymes like glutaminase, preventing cancer cells from utilizing glutamine.

Recent Research Findings

A study published in the Journal of Biological Chemistry by Brazilian researchers investigated the resistance of some TNBCs to CB-839. They hypothesized that resistant cancers depend on alternative nutrients for growth. By comparing sensitive and resistant TNBC cells, they discovered that lipid metabolism genes were more active in resistant cells, indicating an increased reliance on fatty acids.

The researchers further explored this by treating resistant cells with both CB-839 and etomoxir, an inhibitor of carnitine palmitoyltransferase-1 (CPT-1), which disrupts fatty acid metabolism. The combined treatment significantly reduced cell proliferation rates and induced cell death, suggesting promising avenues for new therapeutic approaches.

Implications for Future Research

The findings from this study offer a potential pathway for developing new treatment strategies for triple-negative breast cancer. While the results are encouraging, further investigation through animal models and clinical trials is necessary to validate these approaches. This research can also aid in characterizing TNBC, ultimately enhancing diagnosis and treatment options for patients.

Conclusion

Understanding the metabolic needs of cancer cells opens new doors for innovative treatments. By targeting nutrient pathways, researchers aim to develop strategies that could significantly impact the management of aggressive cancers like triple-negative breast cancer.

References

Carey, L., Winer, E., Viale, G., Cameron, D., & Gianni, L. (2010). Triple-negative breast cancer: disease entity or title of convenience? Nature Reviews Clinical Oncology, 7, 683-692. doi:10.1038/nrclinonc.2010.154

Bernardi, R. & Gianni, L. (2014). Hallmarks of triple negative breast cancer emerging at last? Cell Research, 24, 904-905. doi:10.1038/cr.2014.61

Hanahan, D. & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144, 646-674. doi:10.1016/j.cell.2011.02.013

Lukey, M. J., Wilson, K. F., & Cerione, R. A. (2013). Therapeutic strategies impacting cancer cell glutamine metabolism. Future Medicinal Chemistry, 5, 1685-1700.

Matés, J. M., Campos-Sandoval, J. A. & Márquez, J. (2018). Glutaminase isoenzymes in the metabolic therapy of cancer. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer.

Santos, C. R. & Schulze, A. (2012). Lipid metabolism in cancer. The FEBS Journal, 279, 2610-2623.

dos Reis, L. M. et al. (2019). Dual inhibition of glutaminase and carnitine palmitoyltransferase decreases growth and migration of glutaminase inhibition–resistant triple-negative breast cancer cells. Journal of Biological Chemistry. jbc.RA119.008180.